We are pleased to announce that Kaken Pharmaceutical Co., Ltd. (Tokyo, Japan, President: Shiro Inui) and Chiron Corporation (Emeryville, California) have signed a license agreement on bFGF (FGF-2).
Through the license agreement with Chiron, Kaken has obtained the rights to develop, manufacture and sell bFGF products on a worldwide basis, having previously obtained rights to bFGF in Japan and other Asian countries.
Kaken has been conducting research and development on regenerative medicine using recombinant human bFGF for more than a decade, resulting in the success of the commercialization of a wound-healing drug, FIBLAST SPRAY, in 2001. Kaken is also proceeding with clinical study on periodontitis and bone fractures with bFGF.
Kaken will endeavor to globally develop bFGF products, at least partly in collaboration with its overseas partners, based on know-how of bFGF that it has accumulated through its R&D.